The global AI in ophthalmology market size was valued at USD 283.09 million in 2025 and is projected to grow from USD 383.50 million in 2026 to USD 4,395.52 million by 2034, registering a CAGR of 35.65% during the forecast period (2026–2034). North America dominated the AI in ophthalmology marketwith a marketshare of 51.26% in 2025.
AI in ophthalmology refers to the application of artificial intelligence technologies, including machine learning and deep learning, to assist in the detection, diagnosis, monitoring, and management of eye diseases. These solutions analyze retinal images and other ophthalmic data to identify conditions such as diabetic retinopathy, glaucoma, and cataracts with high accuracy.
The AI in ophthalmology market demand is increasing due to the rising prevalence of vision disorders, growing adoption of AI enabled diagnostics, and emphasis on early detection. Advances in imaging technology and digital healthcare are contributing to AI in ophthalmology market growth.
Download a Free Sample to Explore Detailed Market Insights
The AI in ophthalmology market is indirectly exposed to supply chain disruptions due to its reliance on advanced imaging equipment, semiconductors, sensors, cloud infrastructure, and specialized computing hardware rather than consumable products. Disruptions in the supply of ophthalmic imaging systems, AI-enabled diagnostic devices, electronic components, and medical grade hardware can delay product manufacturing, installations, software integration, and deployment across healthcare facilities worldwide. Global logistics constraints, component shortages, and extended procurement timelines also affect technology providers and healthcare institutions, influencing the pace of AI adoption in ophthalmology. The market is demonstrating a capacity-constrained recovery, supported by improving component availability and continued investments in digital healthcare infrastructure and AI innovation.
Healthcare systems are shifting from specialist dependent eye screening to autonomous AI-powered retinal assessment in primary care, pharmacies, and community health centers, enabling earlier detection of vision-threatening diseases. This transition is improving accessibility, reducing ophthalmologist workload, and accelerating referrals for patients requiring specialized treatment. As healthcare providers emphasize preventive eye care, AI enabled screening is becoming an integral part of routine diabetes and vision health programs. For example, Digital Diagnostics offers an autonomous AI platform that detects diabetic retinopathy without requiring immediate specialist interpretation.
modalities, including fundus photography, optical coherence tomography, and visual field data, instead of relying on single-image diagnostics. This transition enables more comprehensive disease assessment, improves diagnostic confidence, and supports personalized clinical decision making across multiple eye disorders. The trend is strengthening workflow efficiency while expanding AI applications beyond diabetic retinopathy into glaucoma and retinal disease management. For example, ZEISS Medical Ecosystem integrates AI-powered applications such as ZEISS Visual Field Workspace and ZEISS CIRRUS OCT with the FORUM platform, enabling clinicians to combine OCT imaging, visual field results, and fundus data for comprehensive glaucoma and retinal disease assessment within a unified workflow.
The AI in ophthalmology market forecasts continued investment activity driven by the increasing adoption of AI powered diagnostic platforms, expanding retinal screening programs, and growing demand for automated clinical decision support solutions. Investors are focusing on companies developing advanced retinal imaging AI, multimodal ophthalmic analytics, autonomous screening platforms, and robotic ophthalmic technologies that improve diagnostic accuracy, expand access to eye care, and enhance clinical workflow efficiency.
Key Investment and Funding Activities in AI in Ophthalmology Market, 2025
D-Sight
USD 2.2 Million
In February 2026, D-Sight raised USD 2.2 million in a funding round led by Clave Capital to advance ophthalmic technologies for diabetic retinopathy and glaucoma
AI4Eyes
USD 4.7 Million
In January 2026, AI4Eyes secured USD 4.7 million tosupport regulatory approvals, clinical studies, product development, and commercialization of its AI-powered ophthalmology solutions
Optain Health
USD 26 Million (Series A)
In September 2025, Optain Health completed Series A round led by Insight Partners. The funding supports commercialization of its robotic retinal imaging, enterprise deployments, and expansion into new global markets.
ForSight Robotics
USD 125 Million (Series B)
In June 2025, ForSight Robotics raised financing led by Eclipse to accelerate development of its ORYOM AI powered robotic ophthalmic surgery platform and support human clinical trials.
Rising Prevalence of Diabetic Retinopathy and Growing Adoption of AI-enabled Retinal Screening Drives Market
The increasing incidence of diabetes and age-related eye diseases is driving demand for AI-powered ophthalmic diagnostic solutions by creating the need for faster and more scalable screening. Healthcare providers are adopting AI to detect diabetic retinopathy, glaucoma, and age-related macular degeneration at earlier stages, improving clinical outcomes and reducing preventable vision loss. This growing disease burden is increasing the deployment of AI screening programs across hospitals and primary care settings, thereby driving market growth.
Governments and healthcare organizations are expanding AI-assisted retinal screening initiatives to improve access to eye care and address shortages of ophthalmology specialists. AI enables rapid image interpretation, supports large-scale population screening, and reduces delays in diagnosis, increasing demand for AI-based ophthalmology platforms. The integration of these solutions into national diabetes and preventive healthcare programs is accelerating market adoption while improving healthcare efficiency. For example, the Singapore Integrated Diabetic Retinopathy Program uses SELENA+, an AI-based retinal image analysis system developed by the Singapore Eye Research Institute, to support diabetic retinopathy screening and early referral of high-risk patients.
High Integration Costs and Concerns Regarding Data Privacy Restrain Market Expansion
Implementing AI in ophthalmology requires investments in advanced retinal imaging devices, cloud infrastructure, electronic health record integration, and staff training. Many hospitals and eye clinics, particularly in low- and middle-income regions, face budget constraints and lack the digital infrastructure needed to support AI-enabled workflows. Thus, high implementation costs and infrastructure limitations restrain the widespread adoption of AI in ophthalmology solutions.
AI-enabled ophthalmology platforms rely on the collection, storage, and exchange of sensitive patient images and medical records through cloud-based or connected healthcare systems. Compliance with data protection regulations and concerns over cybersecurity increase implementation complexity and operational costs for healthcare providers. Thus, data privacy and cybersecurity challenges restrain the broader adoption of AI in ophthalmology solutions.
AI-assisted Home OCT Monitoring and AI-powered Clinical Trial Optimization Offer Growth Opportunities to Market Players
The shift toward home-based monitoring of retinal diseases is creating new opportunities for companies developing AI-powered ophthalmic monitoring platforms and remote disease management solutions. AI enables continuous analysis of retinal scans captured outside hospitals, allowing clinicians to detect disease progression earlier and optimize treatment intervals. For example, the Notal Vision Home OCT system, supported by the SCANLY Home OCT AI platform, enables patients with neovascular age-related macular degeneration to perform self-scans at home while AI automatically identifies retinal fluid changes and alerts physicians for timely intervention. The expansion of remote retinal monitoring is expected to create long-term growth opportunities for AI-enabled ophthalmic diagnostics and digital eye care ecosystems.
The increasing use of AI in ophthalmic drug development is creating significant opportunities for AI developers, imaging software providers, and pharmaceutical companies involved in retinal disease therapies. AI can automatically identify eligible patients, quantify retinal biomarkers, and monitor disease progression from OCT and fundus images, reducing trial timelines and improving endpoint consistency. =
Algorithm Performance Variability and Complex Clinical Workflow Integration Challenges Market Growth
A major challenge for the AI in ophthalmology market is maintaining consistent diagnostic performance across different imaging devices, patient populations, and clinical environments. AI models trained on specific datasets may experience reduced accuracy when deployed in geographically diverse healthcare settings or with varying image quality. This requires continuous algorithm validation, dataset expansion, and software updates, increasing development costs and slowing large-scale commercialization across global healthcare systems.
Integrating AI solutions into existing ophthalmology workflows remains challenging due to compatibility issues with electronic health records, imaging platforms, and hospital IT infrastructure. Many clinicians also require transparent AI outputs and clinical evidence before incorporating AI recommendations into routine practice. These implementation barriers increase deployment complexity, extend procurement cycles, and delay widespread adoption of AI-enabled ophthalmic diagnostic solutions across healthcare organizations.
By product type, the AI-integrated imaging devices segment accounted for a share of 37.93% in 2025, owing to seamless integration of image acquisition and automated AI analysis within a single workflow, reducing diagnostic delays and operator dependency. Their compatibility with OCT and fundus imaging systems, along with increasing deployment in hospital-based screening programs, further supports market leadership.
The software segment is expected to grow at a CAGR of 36.79% during the forecast period, driven by vendor-neutral compatibility with existing ophthalmic imaging devices and cloud-based deployment that eliminates major hardware investments. Continuous algorithm updates and subscription-based business models further accelerate adoption across multi-site healthcare networks.
By technology, the machine learning segment accounted for a share of 34.47%, supported by its ability to accurately recognize disease patterns from large ophthalmic image datasets while continuously improving through clinical data refinement. Broad commercial use across diabetic retinopathy, glaucoma, and retinal disease screening further strengthens adoption.
The context-aware computing segment is expected to grow at a CAGR of 36.08% during the forecast period, driven by its capability to combine patient history, imaging findings, and clinical parameters for personalized diagnostic recommendations. Intelligent workflow prioritization and integration with connected healthcare systems further support market expansion.
By application, the disease detection & monitoring segment accounted for a share of 60.21% in 2025 due to increasing demand for early diagnosis and continuous monitoring of chronic retinal diseases requiring periodic evaluation. Automated comparison of sequential retinal images enables objective disease progression assessment and supports timely clinical interventions.
The surgical planning & outcome prediction segment is expected to grow at a CAGR of 36.11% during the forecast period, driven by AI-assisted evaluation of ocular biometrics, corneal measurements, and retinal anatomy for personalized surgical planning. Rising cataract and refractive surgery volumes further increase demand for predictive decision-support technologies.
By end user, hospitals accounted for a share of 38.14% in 2025, as they possess advanced ophthalmic imaging infrastructure, multidisciplinary clinical teams, and centralized digital healthcare systems. High patient volumes also maximize utilization of AI-assisted diagnostic workflows across multiple ophthalmology departments.
The ophthalmic clinics segment is expected to grow at a CAGR of 36.40% during the forecast period, as private eye care providers increasingly adopt AI to improve consultation efficiency and reduce diagnostic turnaround times. Compact AI-enabled imaging systems and expanding outpatient eye screening services further support rapid adoption across specialty clinics.
North America: Market Dominance Led by High Concentration of AI Medical Technology Developers and Growing Investments in Digital Health
The North America AI in ophthalmology market accounted for the largest regional share of 51.26% in 2025, driven by a high concentration of AI medical technology developers, widespread commercialization of AI-enabled ophthalmic solutions, and strong availability of advanced retinal imaging infrastructure. The region also benefits from favorable regulatory frameworks, extensive integration of digital health technologies, significant healthcare IT investments, a large base of ophthalmologists and optometrists, and increasing adoption of value-based eye care models that support AI-assisted clinical decision-making.
The US AI in ophthalmology market was valued at USD 126.25 million in 2025, driven by the implementation of AI-assisted diabetic retinopathy screening, growing demand for early detection of age-related eye diseases, and continued investment in digital healthcare technologies. Healthcare providers are adopting autonomous AI systems to improve diagnostic efficiency, reduce specialist workload, and expand access to ophthalmic care in primary care settings. The country's strong ecosystem of academic medical centers, AI developers, ophthalmic imaging manufacturers, and supportive regulatory environment continues to accelerate commercialization and clinical adoption.
The Canada AI in ophthalmology market size was valued at USD 18.86 million in 2025, supported by growing investments in digital health, expanding teleophthalmology services, and increasing adoption of AI-assisted retinal disease screening across provincial healthcare systems. Healthcare providers are leveraging AI to improve access to specialist eye care for remote and underserved populations while enhancing diagnostic efficiency. Canada's publicly funded healthcare system, emphasis on preventive screening, and expanding collaborations between research institutions and healthcare providers continue to support the adoption of AI-powered ophthalmic technologies.
Asia Pacific: Fastest Growth Driven by Expanding Community-based Eye Care Networks and Increasing Diabetic Population
The Asia Pacific AI in ophthalmology market is expected to grow at a CAGR of 37.19% during the forecast period, showcasing the fastest regional growth. Growth is supported by expanding community-based eye care networks, increasing government investments in AI healthcare, and rising localization of ophthalmic AI solutions. Singapore's National AI Strategy 2.0 prioritizes AI adoption in healthcare, while countries including South Korea, Singapore, and Australia continue integrating AI into digital health ecosystems, strengthening regional market expansion.
The China AI in ophthalmology market was valued at USD 15.65 million in 2025, supported by the country's "Internet + Healthcare" strategy, rapid commercialization of domestically developed AI medical software, and large provincial medical alliances promoting digital diagnostics. Companies such as Airdoc have deployed AI retinal screening solutions across thousands of primary healthcare facilities, enabling large-scale chronic disease screening and accelerating adoption of ophthalmic AI technologies.
The India AI in ophthalmology market was valued at USD 8.01 million in 2025, fueled by an increasing diabetic population, an expanding network of specialty eye hospitals, and increasing integration of AI into the National Programme for Control of Blindness and Visual Impairment (NPCBVI). Rising investments in digital health under the Ayushman Bharat Digital Mission (ABDM), growing teleophthalmology services, and increasing deployment of portable retinal imaging across urban and rural healthcare facilities continue to strengthen market adoption.
The Japan AI in ophthalmology market was valued at USD 9.24 million in 2025, supported by strong domestic expertise in ophthalmic imaging, high adoption of precision diagnostics, and close collaboration between industry and academic institutions. Topcon Healthcare integrates AI-enabled analytics into its Harmony digital health platform, allowing clinicians to combine multimodal ophthalmic data for streamlined retinal disease management across hospitals and specialty eye clinics.
The AI in ophthalmology market competitive landscape is moderately fragmented, comprising established medical device manufacturers, AI software developers, ophthalmic imaging providers, and emerging digital health startups. Established players primarily compete through comprehensive product portfolios, integration with ophthalmic imaging systems and hospital workflows, clinical validation, and strategic collaborations with healthcare providers and research institutions. Emerging companies focus on developing disease-specific AI algorithms, autonomous screening solutions, and cloud-based diagnostic platforms. The AI in ophthalmology market ecosystem is driven by technological innovation, diagnostic accuracy, interoperability with electronic health records, data security, and scalability.
January 2026: Optomed and Aireen announced a strategic partnership and received EU approval for integrating the Optomed Lumo handheld fundus camera with Aireen's CE-marked AI algorithm for diabetic retinopathy screening, enabling commercial deployment across European healthcare markets.
Customize This Report to Match Your Strategic Objectives
Author's Details
Senior Research Associate
Dhanashri Bhapakar is a Senior Research Associate with 3+ years of experience in the Biotechnology sector. She focuses on tracking innovation trends, R&D breakthroughs, and market opportunities within biopharmaceuticals and life sciences. Dhanashri’s deep industry knowledge enables her to provide precise, data-backed insights that help companies innovate and compete effectively in global biotech markets.
We are featured on:
sales@straitsresearch.com